Business
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
Medice brings extensive expertise in nephrology and an established European dialysis businessAkebia to receive a $10 million upfront payment, potential for up
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"Medice brings extensive expertise in nephrology and an established European dialysis businessAkebia to receive a $10 million upfront payment, potential for up to $100 million in commercial milestone payments, and tiered royalties up to 30% of net sales in dialysisAkebia retains majority of economics in non-dialysis indication if approved by EMA and retains rights to all other indications CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG (Medice – The Health Family), for Medice to market Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by Akebia to treat anemia due to chronic kidney disease (CKD), in Europe. Akebia is retaining the rights to develop and commercialize in Europe for all other indications. The exclusive license agreement grants Medice the rights to market and sell Vafseo in the European Economic Area in addition to the United Kingdom, Switzerland and Australia. Akebia will receive an upfront payment of $10 million, commercial milestone payments up to $100 million, and tiered royalty payments up to 30% of net sales.\n\n \n \n \n \n \n \n\n \n\"We are thrilled to partner with Medice to bring Vafseo to market in Europe this year,\" said John P. Butler, Chief Executive Officer of Akebia. \"Medice specializes in renal and anemia care and has deep commercial expertise gained by building a successful portfolio in the dialysis space. We believe Vafseo has the potential to be a centerpiece of Medice's portfolio of products for dialysis patients. Our collaboration also provides the flexibility to pursue additional indications to maximize value for Akebia while potentially serving many more patients.\"\n\"We're eager to bring Vafseo to market in Europe as we believe dialysis patients with anemia due to CKD could benefit from additional therapeutic options,\" said Dr. Richard Ammer, Chief Executive Officer of Medice. \"We look forward to working closely with Akebia as we prepare for a commercial launch in dialysis this year.\"\nAnemia associated with CKD, common in patients on dialysis, is a debilitating condition which may be associated with many adverse clinical...